Limb ulcer newco Ilkos raises C$21M

Limb ulcer company Ilkos Therapeutics Inc. (Laval, Quebec) raised C$21 million ($15.9 million) in a venture round. CTI Life Sciences Fund, Fonds de solidarite FTQ and Servier Canada each invested C$7 million ($5.3 million).

The start-up has an exclusive, worldwide license from Servier (Neuilly-sur-Seine, France) to S42909, an oral NADPH oxidase inhibitor. Ilkos said Servier had de-prioritized S42909 for strategic reasons. ...